Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study (EAGLET-CS)
EAGLET-CS Pilot: Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mark Neuman, MD
- Phone Number: 215-746-7468
- Email: eagletadmin@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Hospital of the University of Pennsylvania
-
Contact:
- Mark Neuman
- Phone Number: 2156624000
- Email: mark.neuman@uphs.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 18 or older undergoing non-emergent cesarean delivery with primary neuraxial (epidural, spinal, or CSE) anesthesia. Eligible patients will be those who report severe pain during surgery, defined as pain that does not resolve with 2 trials of first-line pharmacologic therapies (e.g., epidural supplementation with local anesthetics; intravenous opioid analgesics).
Exclusion Criteria:
- We will exclude patients who require induction of general anesthesia prior to umbilical cord clamping and by clinician determination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: General anesthesia
Comparator 1: Standard-care general anesthesia: medically induced unconsciousness with breathing tube placement.
|
standard of care general anesthesia
|
|
Active Comparator: Intravenous sedation
Comparator 2: Time-limited trial of standard care minimal-to-moderate intravenous sedation, with conversion to general anesthesia if pain persists.
|
standard of care intravenous anesthesia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Consent
Time Frame: From hospital admission through day of delivery
|
Study consent rate, defined as the number of patients consenting to participation among those approached for enrollment.
|
From hospital admission through day of delivery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients meeting all inclusion criteria out of all screened
Time Frame: From hospital admission through day of delivery
|
Percentage of patients meeting all inclusion criteria out of all screened
|
From hospital admission through day of delivery
|
|
Randomization
Time Frame: From hospital admission through day of delivery
|
Percentage of consenting patients who undergo study randomization
|
From hospital admission through day of delivery
|
|
Quality of postoperative recovery
Time Frame: Postoperative day 0, 1, 2, or 3
|
Quality of postoperative recovery via 11-item Obstetric Quality of Recovery Scoring Tool minimum score 0 and maximum score 110.
A higher score means better.
|
Postoperative day 0, 1, 2, or 3
|
|
Satifaction with anesthesia
Time Frame: Postoperative day 0, 1, 2, or 3
|
Satisfaction with anesthesia care via 11-item Obstetric Quality of Recovery Scoring Tool minimum score 0 and maximum score 110.
A higher score means better.
|
Postoperative day 0, 1, 2, or 3
|
|
Severity and duration of pain
Time Frame: Postoperative day 0, 1, 2, or 3
|
Reported severity and duration of pain during surgery via 5-item SONAR (Snapshot Obstetric Anesthesia National Research Project) Maternal Comfort Scale.
Minimum score 5 and Maximum score 35.
A higher score means better.
|
Postoperative day 0, 1, 2, or 3
|
|
Adverse events
Time Frame: Randomization through postoperative day 30
|
Postoperative serious adverse events via chart review
|
Randomization through postoperative day 30
|
|
Length of stay
Time Frame: Randomization through postoperative day 30
|
Post-randomization hospital length of stay via chart review
|
Randomization through postoperative day 30
|
|
Need for intensive care
Time Frame: Randomization through postoperative day 30
|
Need for maternal intensive care via chart review
|
Randomization through postoperative day 30
|
|
New PTSD (Posttraumatic Stress Disorder) symptoms
Time Frame: Postoperative 6 week
|
New PTSD (Posttraumatic Stress Disorder) symptoms at 6 weeks after delivery via PCL-5 (Posttraumatic Stress Disorder Checklist for DSM-5) Minimum score 0 and maximum score 80.
A higher score means worse.
|
Postoperative 6 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Trauma and Stressor Related Disorders
- Mental Disorders
- Stress Disorders, Traumatic
- Wounds and Injuries
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Anesthetics
- Central Nervous System Depressants
- Pharmacologic Actions
- Chemical Actions and Uses
- Therapeutic Uses
- Central Nervous System Agents
- Anesthetics, General
- Anesthetics, Intravenous
Other Study ID Numbers
Other Study ID Numbers
- 859498
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.